J P Crown

Summary

Country: Ireland

Publications

  1. doi request reprint Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    J Crown
    All Ireland Cooperative Oncology Research Group, Dublin, Ireland
    Ann Oncol 24:2005-11. 2013
  2. pmc A gene expression profile indicative of early stage HER2 targeted therapy response
    Fiona O'Neill
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 12:69. 2013
  3. pmc Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
    Fiona O'Neill
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 11:41. 2012
  4. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
  5. pmc Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice
    Agnieszka M Zagozdzon
    Cancer Biology and Therapeutics Group, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
    BMC Cancer 12:209. 2012
  6. ncbi request reprint Emerging targeted therapies in triple-negative breast cancer
    J Crown
    St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 23:vi56-65. 2012
  7. pmc Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
    Alex J Eustace
    National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
    J Transl Med 6:53. 2008
  8. pmc The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
  9. pmc Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
    Naomi Walsh
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    BMC Urol 9:6. 2009
  10. doi request reprint Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
    John P Crown
    St Vincent s University Hospital, Dublin, Ireland
    Breast Cancer Res Treat 112:317-25. 2008

Collaborators

Detail Information

Publications47

  1. doi request reprint Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    J Crown
    All Ireland Cooperative Oncology Research Group, Dublin, Ireland
    Ann Oncol 24:2005-11. 2013
    ....
  2. pmc A gene expression profile indicative of early stage HER2 targeted therapy response
    Fiona O'Neill
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 12:69. 2013
    ....
  3. pmc Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
    Fiona O'Neill
    Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Mol Cancer 11:41. 2012
    ..In order to establish a possible gene expression response to lapatinib, a panel of breast cancer cell lines with varying sensitivity to lapatinib were analysed using a combination of microarray and qPCR profiling...
  4. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
    ....
  5. pmc Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice
    Agnieszka M Zagozdzon
    Cancer Biology and Therapeutics Group, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
    BMC Cancer 12:209. 2012
    ..There is a crucial need for making these previously generated models suitable for modern methods of tumour visualisation and monitoring, e.g. by bioluminescence-based techniques. This approach was successfully used in the current study...
  6. ncbi request reprint Emerging targeted therapies in triple-negative breast cancer
    J Crown
    St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 23:vi56-65. 2012
    ..These and other targeted therapies represent a new approach to TNBC therapy...
  7. pmc Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
    Alex J Eustace
    National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
    J Transl Med 6:53. 2008
    ..Dasatinib, a multi-target kinase inhibitor, is currently approved for the treatment of chronic myeloid leukaemia and has shown promising results in preclinical studies in a number of solid tumours...
  8. pmc The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
    ..Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer...
  9. pmc Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
    Naomi Walsh
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    BMC Urol 9:6. 2009
    ..The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease...
  10. doi request reprint Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
    John P Crown
    St Vincent s University Hospital, Dublin, Ireland
    Breast Cancer Res Treat 112:317-25. 2008
    ..To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes...
  11. ncbi request reprint Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy
    John Crown
    St Vincent s University Hospital, Dublin, Ireland
    Breast Cancer Res Treat 79:S11-8. 2003
    ....
  12. ncbi request reprint Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer
    John Crown
    St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Lancet 364:1299-300. 2004
  13. ncbi request reprint Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
    John Crown
    St Vincent s University Hospital, 4, Dublin, Ireland
    Lancet 362:677-8. 2003
  14. ncbi request reprint Docetaxel: overview of an active drug for breast cancer
    J Crown
    St Vincent s Hospital, Dublin, Ireland
    Oncologist 6:1-4. 2001
    ..Comparative cytotoxicity data suggest greater potency. These factors may help explain the clinical differences that have been observed between the taxanes in patients with breast cancer...
  15. ncbi request reprint Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer
    J Crown
    St Vincent s Hospital, Dublin, Ireland
    Oncologist 6:17-21. 2001
    ..Forty-two percent of the patients studied also had prior exposure to a taxane. Weekly gemcitabine plus monthly docetaxel is feasible and active, as is the combination of docetaxel q 3 weeks with daily oral capecitabine...
  16. ncbi request reprint Expanding options in breast cancer
    J P Crown
    St Vincent s Hospital, Dublin, Ireland
    Anticancer Drugs 10:S19-24. 1999
    ..Given that docetaxel appears to be the most active single agent in metastatic breast cancer, there is a compelling case for the drug to be evaluated in the adjuvant setting and such studies are ongoing...
  17. ncbi request reprint The taxanes: an update
    J Crown
    St Vincent s University Hospital, Dublin, Ireland
    Lancet 355:1176-8. 2000
    ..Paclitaxel has recently been approved in the USA for the adjuvant treatment of early stage node-positive breast carcinoma...
  18. ncbi request reprint The platinum agents: a role in breast cancer treatment?
    J P Crown
    Department of Medical Oncology, St Vincent s University Hospital, Dublin, Ireland
    Semin Oncol 28:28-37. 2001
    ....
  19. ncbi request reprint MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer
    S Roy
    St Vincent s University Hospital, Dublin 4, Ireland
    Anticancer Res 27:1325-30. 2007
    ..The purpose of this study was to investigate the prevalence of expression of genes encoding drug efflux pumps, MDR1 and MRP-1, at both the mRNA and protein levels, in this type of cancer...
  20. ncbi request reprint Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy
    J P O'Dwyer
    Department of Neurology, St Vincent s University Hospital, Dublin 4, Ireland
    Neurology 65:331-2. 2005
  21. doi request reprint TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer
    P Doolan
    National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
    Tumour Biol 30:200-9. 2009
    ..However, many such biomarkers have yet to be identified and evaluated. The aim of this study was to investigate the relevance of 3 such putative biomarkers...
  22. doi request reprint ADAM-17 predicts adverse outcome in patients with breast cancer
    P M McGowan
    Department of Pathology, Laboratory Medicine, Conway Institute, University College Dublin, Dublin 4, Ireland
    Ann Oncol 19:1075-81. 2008
    ..Our results are further evidence that ADAM-17 is involved in breast cancer progression and thus provides further impetus for exploiting ADAM-17 as new target for cancer treatment...
  23. pmc SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue
    S Kennedy
    St Vincent s University Hospital, Dublin 4, Ireland
    Br J Cancer 98:1641-5. 2008
    ..This suggests that SNIP/p140Cap may be a useful diagnostic and prognostic marker for breast cancer and its expression in breast cancer, but not in normal breast tissue, suggests that it may have potential as a therapeutic target...
  24. ncbi request reprint Prospects for non-immunological molecular therapeutics in melanoma
    A J Eustace
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland
    J BUON 15:9-18. 2010
    ..Progress on preclinical and clinical evaluation of these novel targets in melanoma will be reviewed...
  25. ncbi request reprint Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
    B M Ryan
    School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Ann Oncol 17:597-604. 2006
    ..In this study we (a) evaluated the association between survivin and HER2, vascular endothelial growth factor (VEGF) and uPA/PAI-1 expression and (b) defined its effect on clinical outcome in a large breast cancer patient cohort...
  26. pmc Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA
    E McKiernan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Br J Cancer 99:1644-50. 2008
    ..007, Mann-Whitney U-test). Increasing concentrations of PKCdelta mRNA were associated with reduced overall patient survival (P=0.004). Our results are consistent with a role for PKCdelta in breast cancer progression...
  27. pmc Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer
    B Ryan
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Br J Cancer 92:120-4. 2005
    ..Our results suggest that the different forms of survivin may have different roles in apoptosis in breast cancer...
  28. ncbi request reprint Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer
    M F Dillon
    Department of Surgery, St Vincent s University Hospital, Dublin, Ireland
    J Med Screen 11:130-4. 2004
    ..We sought to evaluate whether surgical intervention in patients with screen-detected breast cancer differed from those with clinically detected tumours...
  29. ncbi request reprint 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study
    Antonio Fabiano Ferreira Filho
    Jules Bordet Institute, Brussels, Belgium
    Anticancer Res 22:2471-6. 2002
    ..Docetaxel has proven efficacy in metastatic breast cancer. In this pilot study, we explored the efficacy/feasibility of docetaxel-based sequential and combination regimens as adjuvant therapy of node-positive breast cancer...
  30. ncbi request reprint Chemotherapy for metastatic breast cancer-report of a European expert panel
    John Crown
    Vincent s University Hospital, Dublin, Ireland
    Lancet Oncol 3:719-27. 2002
    ..Novel oral therapies have now been developed and are being used increasingly in patients whose disease has progressed following taxane therapy...
  31. ncbi request reprint Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
    Mark D Pegram
    Oncology Research Network, David Geffen School of Medicine, and Division of Hematology Oncology, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:759-69. 2004
    ....
  32. ncbi request reprint Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience
    John Crown
    Medical Oncology Research Unit, St Vincent s University Hospital, Dublin, Ireland
    Oncologist 9:24-32. 2004
    ....
  33. ncbi request reprint Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial
    Robert C F Leonard
    South West Wales Cancer Institute, Singleton Hospital, Swansea, Wales, UK
    J Natl Cancer Inst 96:1076-83. 2004
    ..We compared the benefits of a single cycle of high-dose chemotherapy and the benefits of conventional chemotherapy in patients with high-risk breast cancer in a prospective, unblinded, randomized trial...
  34. ncbi request reprint Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel
    Josephine Ballot
    J Natl Cancer Inst 95:831-2. 2003
  35. doi request reprint Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
    Prudence Francis
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
    J Natl Cancer Inst 100:121-33. 2008
    ..The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel...
  36. ncbi request reprint Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study
    T R Jeffry Evans
    Cancer Research United Kingdom Department of Medical Oncology, University of Glasgow, Beatson Laboratories, Garscube Estate, Switchback Rd, Glasgow G61 1BD, United Kingdom
    J Clin Oncol 23:2988-95. 2005
    ..CONCLUSION In contrast to the positive results reported for sequential docetaxel after AC as primary chemotherapy of breast cancer, our data do not suggest a benefit for simultaneous AD over AC...
  37. ncbi request reprint EGFR and HER-2 antagonists in breast cancer
    Norma O'Donovan
    National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
    Anticancer Res 27:1285-94. 2007
    ..This may be due to difficulty in selecting the appropriate patient population, caused by the lack of definitive predictive markers for response to EGFR inhibition...
  38. ncbi request reprint Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  39. ncbi request reprint Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer
    Miguel Martin
    JAMA 294:2166; author reply 2166-7. 2005
  40. ncbi request reprint Caspase 3 in breast cancer
    Norma O'Donovan
    Department of Medical Oncology, St Vincent s University Hospital, University College Dublin, Dublin 4, Ireland
    Clin Cancer Res 9:738-42. 2003
    ..One of the key mediators of apoptosis is the thiol protease caspase 3. In this investigation, caspase 3 mRNA and protein expression in breast cancer was examined...
  41. ncbi request reprint Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue
    Vanesa Martinez
    National Institute for Cellular Biotechnology NICB, Dublin City University, Dublin 9, Ireland
    Breast Cancer Res Treat 110:521-30. 2008
    ..0028). Multivariate analysis indicated GST A1 expression to be an independent prognostic factor for overall survival (P = 0.045). Our results suggest a possible use of ARNT2 and GST A1 as prognostic breast cancer biomarkers...
  42. ncbi request reprint Prevalence and prognostic and predictive relevance of PRAME in breast cancer
    Padraig Doolan
    National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
    Breast Cancer Res Treat 109:359-65. 2008
    ..Our results suggest that PRAME mRNA expression may be a useful prognostic and predictive marker for breast cancer...
  43. ncbi request reprint High-dose chemotherapy for solid tumors: results of the EBMT
    Giovanni Rosti
    EBMT Solid Tumors Working Party, Chairman Dr G Rosti, Ospedale Civile, Viale Randi 5, 48100, Ravenna, Italy
    Crit Rev Oncol Hematol 41:129-40. 2002
    ..This paper will describe the EBMT Solid Tumors Working Party Registry updated results as well as the main ongoing studies...
  44. ncbi request reprint Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up
    Richard E Power
    The Adelaide and Meath Hospital incorporating the National Children s Hospital, Tallaght, Dublin, Ireland
    Int J Urol 12:378-82. 2005
    ..To highlight the increased risk for pelvic relapse in patients with stage 1 seminoma treated with adjuvant radiotherapy limited to para-aortic template alone...
  45. ncbi request reprint Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel...
  46. ncbi request reprint Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study
    Annemarie Larkin
    National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
    Int J Cancer 112:286-94. 2004
    ..No association was shown between MDR-1 Pgp expression and either RFS or OS time in any subgroup of patients...
  47. ncbi request reprint High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 50:559-63. 2004
    ..CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease...